Pazopanib 400mg
| Product Overview | |
| Generic Name | Pazopanib 400mg |
| Brand Name(s) | Votrient® |
| Product Type | Generic |
| Form | 30 Film-coated oral tablets |
| Strength | 400 mg tablet |
| Therapeutic Class | Kinase inhibitor; VEGF/VEGFR inhibitor / multitargeted tyrosine kinase inhibitor |
| ATC Code | L01EX03 |
| Manufacturing & Regulatory | |
| Manufacturer | Novartis, Cipla, Intas |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.5655.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 5 units |
| Shelf Life | 36 months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| CTD Summary | Not public; request Module 2 / ACTD summary. |
Description
Pazopanib is an oral multitargeted tyrosine kinase inhibitor used in adults for advanced renal cell carcinoma and for advanced soft-tissue sarcoma after prior chemotherapy; efficacy is not established for adipocytic soft-tissue sarcoma or gastrointestinal stromal tumors.
